FSH, inhibin B not accurate predictors of sperm count in childhood cancer survivors

This article originally appeared here.
Share this content:
FSH, Inhibin B Poor Predictors of Sperm Count After Cancer
FSH, Inhibin B Poor Predictors of Sperm Count After Cancer

(HealthDay News) -- Serum levels of follicle-stimulating hormone (FSH) and inhibin B are not good predictors of sperm levels in male survivors of childhood cancer, according to a study published online Feb. 19 in the Journal of Clinical Oncology.

Daniel M. Green, M.D., from the St. Jude Children's Research Hospital in Memphis, Tenn., and colleagues investigated the association of serum levels of FSH and inhibin B with sperm concentration in 275 adult male survivors of childhood cancer who had received gonadotoxic treatment placing them at risk of azoospermia.

Based on receiver operating characteristic analysis, the researchers chose 11.5 mIU/mL FSH and 31 ng/L inhibin B as cutoffs. Using these cutoffs to identify azoospermic survivors, they found that serum FSH levels had a specificity of 74.1 percent and a positive predictive value of 65.1 percent, while serum inhibin B levels had a specificity of 45.0 percent and a positive predictive value of 52.1 percent.

"Neither serum inhibin B nor FSH is a suitable surrogate for determination of sperm concentration in a semen sample," Green and colleagues conclude.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs